Recent progress in Cetuximab-based treatment for Triple-NegativeBreast Cancer

Abstract

This study verifies the preclinical therapeutic effect of YM-1 silencing BAG3 combined with cetuximab targeted at
epidermal growth factor receptor (EGFR) on Triple-Negative Breast Cancer (TNBC ) cell lines both in vitro and in
vivo. TNBC is defined as a unique subtype of breast cancer that leads to an increase in patients with interval cancers
which can be detected annually. In actual research, targeted molecular therapies are involved in the field because of the
immunological heterogeneity of TNBC. YM-1 has a potentially better inhibition target for EGFR instead of BAG3. By
reviewing some existing preclinical research and targeted treatment for TNBC, this study is to propose a novel treatment
target for TNBC based on cetuximab treatment.